^
BIOMARKER:

BRCA1 mutation

i
Other names: BRCA1, BRCC1, PPP1R53, RNF53, Breast cancer 1, early onset




Show legend

Include preclinical:
Triple Negative Breast Cancer
Ovarian Cancer
Breast Cancer
Prostate Cancer
HER2 Negative Breast Cancer
Pancreatic Adenocarcinoma
Pancreatic Cancer
Hormone Receptor Positive Breast Cancer
Solid Tumor
Peritoneal Cancer
Fallopian Tube Cancer
Pancreatic Ductal Adenocarcinoma
Ovarian Serous Adenocarcinoma
Non Small Cell Lung Cancer
Biliary Tract Cancer
Endometrial Cancer
Colorectal Cancer
Germ Cell Tumors
Esophageal Squamous Cell Carcinoma
Renal Cell Carcinoma
Gallbladder Cancer
Gastrointestinal Cancer
Head and Neck Cancer
Cholangiocarcinoma
Uterine Corpus Leiomyosarcoma
Mesothelioma
Lung Cancer
PARP inhibitor
CPB
Immunotherapy + PARP inhibitor
FOLFIRINOX
PD-L1 inhibitor + PARP inhibitor
Immunotherapy
CDK4 inhibitor + CDK6 inhibitor
PARP inhibitor + EZH2 inhibitor
FOLFIRI
CaT
FOLFOX
Androgen receptor inhibitor
olaparib
carboplatin
rucaparib
gemcitabine
capecitabine
vinorelbine tartrate
eribulin mesylate
pegylated liposomal doxorubicin
doxorubicin hydrochloride
paclitaxel
ABT-888
niraparib
talazoparib
CX-5461
avelumab + talazoparib
pamiparib
olaparib + capivasertib
bevacizumab + olaparib
ribociclib
IDE161
carboplatin + paclitaxel
IMP4297
olaparib + durvalumab
AZD1775
BSI 201
cisplatin + gemcitabine
fluzoparib
olaparib + AZD6738
tislelizumab + pamiparib
olaparib + ACR-368
pembrolizumab
JPI-547
rivoceranib + fluzoparib
SC10914
rucaparib + copanlisib
ipilimumab + niraparib
talazoparib + PF-05212384
nivolumab + rucaparib
bevacizumab + olaparib + durvalumab
olaparib + tremelimumab
atezolizumab
enzalutamide capsule
carboplatin + pegylated liposomal doxorubicin
abiraterone/niraparib
rucaparib + sacituzumab govitecan-hziy
nivolumab
M6620
docetaxel
lurbinectedin
bevacizumab + niraparib + dostarlimab-gxly
avelumab
olaparib + AZD1775
melphalan
temozolomide + ABT-888
olaparib + durvalumab + tremelimumab
NOV 1401
anlotinib + niraparib
olaparib + AT13387
cisplatin
trabectedin
olaparib + cediranib
pegylated liposomal doxorubicin + trabectedin
gemcitabine + albumin-bound paclitaxel
tocilizumab
oxaliplatin
cetuximab + olaparib
pembrolizumab + olaparib
pembrolizumab + niraparib
ACR-368
BAY 1895344
bevacizumab
STAR-001
palbociclib
nedaplatin
gemcitabine + eribulin mesylate
fulvestrant + anastrozole
niraparib + AZD1775
BGB324
olaparib + palbociclib
olaparib + APG-1387
abemaciclib
carboplatin + docetaxel
olaparib + RG6614
osimertinib
neratinib + niraparib
olaparib + neratinib
olaparib + VIO-01
niraparib + M1774
AZD5305
olaparib + PCM-075
TQB3823
talazoparib + LY294002
ART558
PARP inhibitor + RK-33